指南与共识血脂与心血管预防

2018 AHA/ACC血胆固醇管理指南的系统综述:非他汀类调脂治疗的证据

Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
指南 / 共识 · Circulation · 2018-11-10

结果显示依折麦布和PCSK9抑制剂可降低ASCVD事件,而烟酸和CETP抑制剂无获益证据。

要点

  • 依折麦布联合辛伐他汀较辛伐他汀单药降低主要终点1.8%(7年NNT=56)。
  • PCSK9抑制剂evolocumab和alirocumab分别降低主要终点1.5%和1.6%。
  • 烟酸和CETP抑制剂在他汀基础上未显示ASCVD获益证据。

核心结论

  • 在他汀基础上加用依折麦布或PCSK9抑制剂可降低ASCVD事件,而烟酸或CETP抑制剂无获益证据。

主要发现

  • IMPROVE-IT中依折麦布/辛伐他汀较辛伐他汀7年降低主要终点1.8%(HR 0.90,95%CI 0.84-0.96,NNT=56)。
  • FOURIER中evolocumab较安慰剂2.2年降低主要终点1.5%(HR 0.80,95%CI 0.73-0.88,NNT=67)。
  • ODYSSEY OUTCOMES中alirocumab较安慰剂2.8年降低主要终点1.6%(HR 0.86,95%CI 0.79-0.93,NNT=63)。
  • 依折麦布和PCSK9抑制剂的不良事件风险与对照组无差异。
  • 烟酸和CETP抑制剂在他汀基础上未显示ASCVD风险改善或不良事件差异。

关键数值与推荐

  • 主要终点为致命性心血管事件、非致命性心肌梗死和非致命性卒中的复合终点。

临床怎么用

  • 对ASCVD高危或确诊患者,在他汀基础上可考虑加用依折麦布或PCSK9抑制剂以进一步降低事件风险。
  • 不推荐常规加用烟酸或CETP抑制剂用于ASCVD风险降低。

局限性

  • 10项随机对照试验的样本量、随访时长和报告的主要终点存在显著差异,限制直接比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The 2013 American College of Cardiology/American Heart Association guidelines for the treatment of blood cholesterol found little evidence to support the use of nonstatin lipid-modifying medications to reduce atherosclerotic cardiovascular disease (ASCVD) events. Since publication of these guidelines, multiple randomized controlled trials evaluating nonstatin lipid-modifying medications have been published. METHODS: We performed a systematic review to assess the magnitude of benefit and/or harm from additional lipid-modifying therapies compared with statins alone in individuals with known ASCVD or at high risk of ASCVD. We included data from randomized controlled trials with a sample size of >1 000 patients and designed for follow-up >1 year. We performed a comprehensive literature search and identified 10 randomized controlled trials for intensive review, including trials evaluating ezetimibe, niacin, cholesterol-ester transfer protein inhibitors, and PCSK9 inhibitors. The prespecified primary outcome for this review was a composite of fatal cardiovascular events, nonfatal myocardial infarction, and nonfatal stroke. RESULTS: The cardiovascular benefit of nonstatin lipid-modifying therapies varied significantly according to the class of medication. There was evidence for reduced ASCVD morbidity with ezetimibe and 2 PSCK9 inhibitors. Reduced ASCVD mortality rate was reported for 1 PCSK9 inhibitor. The use of ezetimibe/simvastatin versus simvastatin in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) reduced the primary outcome by 1.8% over 7 years (hazard ratio: 0.90; 95% CI: 0.84-0.96], 7-year number needed to treat: 56). The PSCK9 inhibitor evolocumab in the FOURIER study (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) decreased the primary outcome by 1.5% over 2.2 years (hazard ratio: 0.80; 95% CI: 0.73-0.88; 2.2=year number needed to treat: 67). In ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab), alirocumab reduced the primary outcome by 1.6% over 2.8 years (hazard ratio: 0.86; 95% CI: 0.79-0.93; 2.8-year number needed to treat: 63). For ezetimibe and the PSCK9 inhibitors, rates of musculoskeletal, neurocognitive, gastrointestinal, or other adverse event risks did not differ between the treatment and control groups. For patients at high risk of ASCVD already on background statin therapy, there was minimal evidence for improved ASCVD risk or adverse events with cholesterol-ester transfer protein inhibitors. There was no evidence of benefit for the addition of niacin to statin therapy. Direct comparisons of the results of the 10 randomized controlled trials were limited by significant differences in sample size, duration of follow-up, and reported primary outcomes. CONCLUSIONS: In a systematic review of the evidence for adding nonstatin lipid-modifying therapies to statins to reduce ASCVD risk, we found evidence of benefit for ezetimibe and PCSK9 inhibitors but not for niacin or cholesterol-ester transfer protein inhibitors.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Wilson PWF, Polonsky TS, Miedema MD, et al. Systematic Review for the 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2018. PMID: 30586775. doi:10.1161/CIR.0000000000000626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。